Market Overview

Ligand Pharma, Glaxo Confirm PROMACTA Receives FDA Ok for New Indication

Related LGND
Tech Stock Strategist Sean Udall's Take On Apple's Earnings Report
UPDATE: Deutsche Bank Initiates Coverage On Ligand Pharmaceuticals On Growing Royalty Play On Biopharma
Earnings Peek: Stay With Ligand Pharmaceuticals For A Year Or Three (Seeking Alpha)
Related GSK
GlaxoSmithKline Expands Its Portfolio Of Medicines In The US For Patients With Asthma And COPD
Benzinga's Weekend M&A Chatter
Can GlaxoSmithKline Continue Striving in the Face of World Challenges? (GuruFocus)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Food and Drug Administration (FDA) has approved PROMACTA for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based therapy. PROMACTA is the first supportive care treatment available to patients who are ineligible or poor candidates for interferon-based therapy due to their low blood platelet counts. PROMACTA in combination with interferon-based therapy has been shown to improve a patient's chance of achieving a sustained virologic response (SVR) or viral cure.

Posted-In: News FDA


Related Articles (LGND + GSK)

Around the Web, We're Loving...

Get Benzinga's Newsletters